Yi Yang1, Tao Guo, Tetsuro Oda, Asima Chakraborty, Le Chen, Hitoshi Uchinoumi, Anne A Knowlton, Bradley R Fruen, Razvan L Cornea, Gerhard Meissner, Donald M Bers. 1. From the Department of Pharmacology (Y.Y., T.G., T.O., H.U., A.A.K., D.M.B.), and Molecular and Cellular Cardiology Division, Department of Medicine (L.C., A.A.K.), University of California, Davis, CA; Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC (A.C., G.M.); and Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN (B.R.F., R.L.C.).
Abstract
RATIONALE: Calmodulin (CaM) associates with cardiac ryanodine receptor type-2 (RyR2) as an important regulator. Defective CaM-RyR2 interaction may occur in heart failure, cardiac hypertrophy, and catecholaminergic polymorphic ventricular tachycardia. However, the in situ binding properties for CaM-RyR2 are unknown. OBJECTIVE: We sought to measure the in situ binding affinity and kinetics for CaM-RyR2 in normal and heart failure ventricular myocytes, estimate the percentage of Z-line-localized CaM that is RyR2-bound, and test cellular function of defective CaM-RyR2 interaction. METHODS AND RESULTS: Using fluorescence resonance energy transfer in permeabilized myocytes, we specifically resolved RyR2-bound CaM from other potential binding targets and measured CaM-RyR2 binding affinity in situ (Kd=10-20 nmol/L). Using RyR2(ADA/+) knock-in mice, in which half of the CaM-RyR2 binding is suppressed, we estimated that >90% of Z-line CaM is RyR2-bound. Functional tests indicated a higher propensity for Ca2+ wave production and stress-induced ventricular arrhythmia in RyR2(ADA/+) mice. In a post-myocardial infarction rat heart failure model, we detected a decrease in the CaM-RyR2 binding affinity (Kd≈51 nmol/L; ≈3-fold increase) and unaltered RyR2 affinity for the FK506-binding protein FKBP12.6 (Kd~0.8 nmol/L). CONCLUSIONS: CaM binds to RyR2 with high affinity in cardiac myocytes. Physiologically, CaM is bound to >70% of RyR2 monomers and inhibits sarcoplasmic reticulum Ca2+ release. RyR2 is the major binding site for CaM along the Z-line in cardiomyocytes, and dissociating CaM from RyR2 can cause severe ventricular arrhythmia. In heart failure, RyR2 shows decreased CaM affinity, but unaltered FKBP 12.6 affinity.
RATIONALE: Calmodulin (CaM) associates with cardiac ryanodine receptor type-2 (RyR2) as an important regulator. Defective CaM-RyR2 interaction may occur in heart failure, cardiac hypertrophy, and catecholaminergic polymorphic ventricular tachycardia. However, the in situ binding properties for CaM-RyR2 are unknown. OBJECTIVE: We sought to measure the in situ binding affinity and kinetics for CaM-RyR2 in normal and heart failure ventricular myocytes, estimate the percentage of Z-line-localized CaM that is RyR2-bound, and test cellular function of defective CaM-RyR2 interaction. METHODS AND RESULTS: Using fluorescence resonance energy transfer in permeabilized myocytes, we specifically resolved RyR2-bound CaM from other potential binding targets and measured CaM-RyR2 binding affinity in situ (Kd=10-20 nmol/L). Using RyR2(ADA/+) knock-in mice, in which half of the CaM-RyR2 binding is suppressed, we estimated that >90% of Z-line CaM is RyR2-bound. Functional tests indicated a higher propensity for Ca2+ wave production and stress-induced ventricular arrhythmia in RyR2(ADA/+) mice. In a post-myocardial infarctionratheart failure model, we detected a decrease in the CaM-RyR2 binding affinity (Kd≈51 nmol/L; ≈3-fold increase) and unaltered RyR2 affinity for the FK506-binding protein FKBP12.6 (Kd~0.8 nmol/L). CONCLUSIONS:CaM binds to RyR2 with high affinity in cardiac myocytes. Physiologically, CaM is bound to >70% of RyR2 monomers and inhibits sarcoplasmic reticulum Ca2+ release. RyR2 is the major binding site for CaM along the Z-line in cardiomyocytes, and dissociating CaM from RyR2 can cause severe ventricular arrhythmia. In heart failure, RyR2 shows decreased CaM affinity, but unaltered FKBP 12.6 affinity.
Authors: K Tanonaka; K I Furuhama; H Yoshida; K Kakuta; Y Miyamoto; W Toga; S Takeo Journal: Am J Physiol Heart Circ Physiol Date: 2001-07 Impact factor: 4.733
Authors: Juan José Arnáiz-Cot; Brooke James Damon; Xiao-Hua Zhang; Lars Cleemann; Naohiro Yamaguchi; Gerhard Meissner; Martin Morad Journal: J Physiol Date: 2013-07-08 Impact factor: 5.182
Authors: Silvia G Priori; Carlo Napolitano; Mirella Memmi; Barbara Colombi; Fabrizio Drago; Maurizio Gasparini; Luciano DeSimone; Fernando Coltorti; Raffaella Bloise; Roberto Keegan; Fernando E S Cruz Filho; Gabriele Vignati; Abraham Benatar; Angelica DeLogu Journal: Circulation Date: 2002-07-02 Impact factor: 29.690
Authors: Jeffrey R Erickson; C Blake Nichols; Hitoshi Uchinoumi; Matthew L Stein; Julie Bossuyt; Donald M Bers Journal: J Biol Chem Date: 2015-08-27 Impact factor: 5.157
Authors: Kafa Walweel; Nieves Gomez-Hurtado; Robyn T Rebbeck; Ye Wint Oo; Nicole A Beard; Peter Molenaar; Cris Dos Remedios; Dirk F van Helden; Razvan L Cornea; Björn C Knollmann; Derek R Laver Journal: J Mol Cell Cardiol Date: 2019-03-27 Impact factor: 5.000
Authors: Ye Win Oo; Nieves Gomez-Hurtado; Kafa Walweel; Dirk F van Helden; Mohammad S Imtiaz; Bjorn C Knollmann; Derek R Laver Journal: Mol Pharmacol Date: 2015-04-28 Impact factor: 4.436